Design, synthesis, and biological evaluation of KA7, a novel quinolone-based sorafenib analogue with potent anticancer and immunomodulatory activities.

RSC Adv · 2025 · PMC12695144 · PMID 41384066

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Similarly, the sorafenib-treated cells showed a highly significant increase in both Annexin V-positive and PI-positive cells among all cell lines treated.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.